Compare CNK & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | INDV |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2007 | 2014 |
| Metric | CNK | INDV |
|---|---|---|
| Price | $29.17 | $30.49 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $32.90 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 3.2M |
| Earning Date | 05-01-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 1.04 | ★ 1.64 |
| Revenue | ★ $3,115,000,000.00 | $1,239,000,000.00 |
| Revenue This Year | $10.82 | N/A |
| Revenue Next Year | $3.68 | N/A |
| P/E Ratio | $28.09 | ★ $18.58 |
| Revenue Growth | 2.15 | ★ 4.29 |
| 52 Week Low | $21.60 | $8.65 |
| 52 Week High | $34.01 | $38.00 |
| Indicator | CNK | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 46.63 |
| Support Level | $24.88 | $29.71 |
| Resistance Level | $30.88 | $35.75 |
| Average True Range (ATR) | 0.99 | 1.31 |
| MACD | 0.15 | 0.14 |
| Stochastic Oscillator | 95.49 | 61.18 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).